Abstract
Background
The indirect costs of Parkinson’s disease (PD) may be larger than direct healthcare costs, and the largest component of indirect costs is income loss related to early retirement. No recent retrospective analysis details PD-related early retirement and income loss in the US.
Objective
We used an observational, matched cohort to study wages and labour force participation over 4 years and to simulate lifetime income losses conditional on being newly diagnosed with PD (naive) or having evidence of increasing disability.
Methods
Actively employed primary beneficiaries of private insurance policies aged 18–64 years with more than two PD diagnoses (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]: 332.x) or one diagnosis and a prescription of an antiparkinsonian drug were selected from a privately insured claims database. Continuous health coverage during analysis periods was required. Naive patients were defined as having no claims history indicative of PD during the year prior to first diagnosis or prescription use. A PD with ambulatory assistance devices (PDAAD) cohort was also followed from the date of first evidence of a wheelchair or walker. Controls without PD were matched on age, sex and region. Survival analysis and Wilcoxon rank sum tests were used to compare rates of early retirement and income loss. A simulation of projected economic loss was conducted for PD cohorts diagnosed at different ages using Bureau of Labor Statistics labour force participation and income data.
Results
Naive PD patients (n = 278) and PDAAD patients (n = 28) were on average aged 53 years and had significantly higher rates of co-morbidities at baseline versus controls. Conditional on being employed, there was no statistical difference in earnings. However, the hazard of early retirement associated with PD was 2.08 (p < 0.001) for the naive cohort and 5.01 (p < 0.001) for the PDAAD cohort. From age 40 to 79 years, earnings losses in year 2009 values were $US569 393, $US188 590, $US35496 and $US2451 for those diagnosed at age 45, 55, 65 and 75 years, respectively. Estimates increased by 9% to 37% when using expected 2018 labour force participation estimates.
Conclusions
The cost of early retirement associated with patients with PD was substantial. Given that the proportion of Americans participating in the labour force in older age groups is expected to increase, PD-related early retirement costs will likely rise.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
National Institute for Health and Clinical Excellence. Parkinson’s disease: quick reference guide. London: NICE, 2006
Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007 Jan 30; 68(5): 384–6
Huse DM, Castelli-Haley J, Orsini LS, et al. Patterns of initial pharmacotherapy for Parkinson’s disease in the United States. J Geriatr Psychiatry Neurol 2006 Jun; 19(2): 91–7
Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003 Jun; 157(11): 1015–22
Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997 Jul; 45(7): 844–9
Le Pen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with parkinson’s disease. Pharmacoeconomics 1999 Jul; 16(1): 59–69
Hagell P, Nordling S, Reimer J, et al. Resource use and costs in a Swedish cohort of patients with Parkinson’s disease. Mov Disord 2002 Nov; 17(6): 1213–20
Keränen T, Kaakkola S, Soataniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003 Jan; 9(3): 163–8
Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics 2005; 23(8): 817–36
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992 Jun; 45(6): 613–9
Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med 1992; 11(14-15): 1871–9
Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972; 34(2): 187–220
Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945; 1: 80–3
Toossi M. Labor force projections to 2018: older workers staying more active. Monthly Labor Review 2009 Nov; 132(11): 30–51
US Census Bureau. Current population survey, 2010 annual social and economic supplement. Selected characteristics of people 15 years old and over by total money income in 2009, work experience in 2009, race, Hispanic origin, and sex (PINC-01) [online]. Available from URL: http://www.census.gov/hhes/www/cpstables/032010/perinc/new01_000.htm [Accessed 2011 Aug 16]
Congressional Budget Office. CBO’s 2011 long-term budget outlook. Washington, DC: CBO, 2011 Jun: 25
Poewe W. The natural history of Parkinson’s disease. J Neurol 2006 Dec; 253Suppl. 7: VII2–6
Shearer J, Green C, Counsell CE, et al. The use of decision-analytic models in Parkinson’s disease: a systematic review and critical appraisal. Appl Health Econ Health Policy 2011 Jul; 9(4): 243–58
Kaltenboeck A, Johnson SJ, Davis MR, et al. Direct costs and survival of Medicare beneficiaries with early and advanced Parkinson’s disease. Under review at Parkinsonism and Related Disorders, and poster presentation at the American Academy of Neurology’s Annual Meeting: 2011 Apr 10-17; Honolulu (HI)
Nordhaus WD. The health of nations: the contribution of improved health to living standards. In: Murphy KM, Topel R, editors. Measuring the gains from medical research: an economic approach. Chicago (IL): University of Chicago Press, 2003: 9–41
Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000 May; 320(7245): 1335
Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997 Feb; 16(1): 1–31
Drummond MF, McGuire A, editors. Economic evaluation in health care: merging theory with practice. New York: Oxford University Press, 2001
Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20(3): 332–42
van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010 Jan; 69Suppl. 1: i89–91
Acknowledgements
Funding for this study was provided by Teva Neuroscience to Analysis Group, Inc. Scott Johnson, Anna Kaltenboeck and Howard Birnbaum are current employees of Analysis Group, Inc. Matthew Davis was an employee of Analysis Group at the time of this analysis. Andrew Siderowf is a neurologist at the University of Pennsylvania who also served as a consultant to, and received speaking honorarium from, Teva Neuroscience. Both ElizaBeth Grubb and Marcy Tarrants are current employees of Teva Neuroscience; ElizaBeth Grubb owns stock and Marcy Tarrants owns stock options in Teva Pharmaceuticals.
Scott Johnson, Matthew Davis, Anna Kaltenboeck, Howard Birnbaum and Andrew Siderowf fulfilled all criteria for authorship and independently conducted all analyses. ElizaBeth Grubb and Marcy Tarrants fulfilled all criteria for authorship but neither had access to research data nor provided editorial input to the manuscript. The authors controlled the decision to write and submit the manuscript for publication. All authors approved the final version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Johnson, S., Davis, M., Kaltenboeck, A. et al. Early retirement and income loss in patients with early and advanced Parkinson’s disease. Appl Health Econ Health Policy 9, 367–376 (2011). https://doi.org/10.2165/11596900-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11596900-000000000-00000